组卷网 > 高中英语综合库 > 主题 > 人与自我 > 健康 > 医疗
题型:阅读理解-阅读单选 难度:0.4 引用次数:162 题号:9018686

China’s domestically developed, long-acting experimental AIDS drug is undergoing a final review by the China Food and Drug Administration, the last stage in the approval process.

Different from traditional oral drugs that require daily use, but it’s a heavy burden for patients to take medicine every day for years. As a result, long-acting drugs are the future direction in developing innovative AIDS medicine. For Chinese patients, the number of oral drugs available in the domestic market is very limited, so there is an urgent need for drugs to solve the problem of drug resistance.

Zhao Yan, a treatment specialist at the National Center for AIDS said seven or eight oral drugs for AIDS are currently provided to patients for free. “The injection solution could give an alternative to patients ... if it could be included in the country’s health insurance system,” she said.

“Now very few patients are using drugs from the health insurance system, both because no differentiated drugs are provided and because the procedure is more complex and could harm their privacy,” she said. “New drugs will be broadly used only if the system can embrace more varieties of drugs.”

Albuvirtide went into the research and development stage in 2002 and entered phase three of clinical trials—a step to assure safety and effectiveness before market approval—in 2014. Phase three is the last round of clinical trials for new drug tests in China. If the drug can pass the reviews of the country’s drug watchdog, usually at least two rounds, it can then enter the market. The time needed for the review ranges from months to years.

Clinical trials showed that the new drug performs even better than the oral drugs being used. Most of the oral drugs for AIDS being used in China are generic drugs developed in the 1970s and „80s that are not so efficient. In terms of safety and effectiveness, evidence so far showed that Albuvirtide is better than most second-line drugs—drugs used when first-line standard drugs fail—in developed countries because of lower toxicity (毒性) and fewer side effects.

Worldwide, a number of long-acting AIDS drug are in development. None has been approved for sale. Only Albuvirtide and a few in the United States have entered phase three of clinical trials.

1. Albuvirtide is ________.
A.a China-developed long-acting oral AIDS drug
B.undergoing a clinical test on dogs to assure its safety
C.more efficient than other AIDS drugs and has fewer side effects
D.the only AIDS drug that has entered the last round of clinical trials
2. Albuvirtide is good news for AIDS patients in China because ________.
A.it’s a new drug and they are not resistant to it
B.it is one of the most effective first-line drugs
C.it has been included in the health insurance system
D.they can keep their privacy by being injected once a week
3. Which of the following statements is FALSE?
A.The research and development of Albuvirtide began in 2002.
B.There are usually three phases in the clinical trial for a new drug.
C.Albuvirtide is now in the stage of carrying out clinical trials.
D.The time needed for review varies from drug to drug.
4. We can infer from the passage that ________.
A.Albuvirtide can spare patients from taking oral drugs every day
B.the health insurance system has room for further improvement
C.most AIDS drugs being used now were developed in last century
D.China is leading the whole world in the field of AIDS research

相似题推荐

阅读理解-阅读单选(约400词) | 较难 (0.4)
名校
文章大意:本文是一篇说明文。文章主要介绍了研究人员发明了一种药丸大小的装置,可以输送精细药物,以帮助那些怕针的人,让他们不需要体验注射药物带来的不适。

【推荐1】Plenty of people hate needles simply because they do not want the discomfort of injection. A new invention could help — for those who are needle-shy, how about taking a pill instead?

Two of the most successful covid-19 vaccines, from Pfizer-BioNTech and Moderna, need to be administered via injections because their active ingredients are fragile molecules of mRNA, which would be quickly destroyed by acids in the stomach if administered orally.

Aware of these challenges, Robert Langer and Giovanni Traverso, engineers at the Massachusetts Institute of Technology (MIT), wondered if it might be possible instead to send mRNA into the stomach inside a protective capsule that is engineered to inject patients from the inside, where they would feel nothing.

The device they invented is the size of a large pill, encased in gelatin (明胶) and shaped like the shell of a tortoise. It carries a needle that is engineered to stick into the lining of the stomach only when the device’s flat section sits level to it. And the needle can then inject its payload painlessly into the stomach wall.

The researchers knew, however, that this trick alone would not be enough for safe passage of the delicate molecules into cells. Naked mRNA is not readily taken up by cells, but needs to be encased inside a protective envelope to gain entry. So, to investigate further, the engineers worked with colleagues at MIT and found three polymers (聚合物) that could carry the mRNA payloads successfully and also support a transfer into living cells.

The engineers loaded these polymer-encased mRNA molecules into their turtle-shell pills, which were then swallowed by six mice. As expected, they subsequently found evidence that the mRNA had transferred successfully into the stomach tissue of all the mice. The researchers then went on to test their technology on pigs, which have stomachs that are very similar to those found in humans. They introduced their turtle-shell pills into three animal sand studied their stomachs a day later. Two showed clear evidence of the mRNA having entered their cells. One did not.

The device shows the potential to get mRNA into the body without the need for an uncomfortable injection in the arm. More work is needed to understand why one trial in the pigs failed to yield results.

1. What are the first two paragraphs mainly about?
A.The protest of the injection.B.The reasons for the research.
C.The application of the research.D.The qualities of the vaccines.
2. Which aspect does the research focus on in Para.4 and Para.5?
A.The delivery of mRNA.B.The protection of cells.
C.The classification of polymers.D.The transformation of molecules.
3. What can we learn from the passage?
A.Those needle-shy will have injection without fear.
B.The device will definitely have a promising future.
C.Further research needs to be conducted on the idea.
D.The turtle-shell pills can guarantee molecule activity.
4. Which can be a suitable title for the passage?
A.A new way to deliver delicate drugsB.Pills to relieve symptoms of covid-19
C.The administration of covid-19 vaccineD.Researches on molecules of mRNA
2022-12-28更新 | 228次组卷
阅读理解-阅读单选(约360词) | 较难 (0.4)

【推荐2】Every year, 1.5 million kids around the world die as a result of not getting vaccines (疫苗). This is partly because transporting and storing medicines can be a huge challenge in some countries.

Anurudh Ganesan, 17, knows this firsthand. When he was a baby in India, his grandparents carried him 10 miles to a health clinic in a remote village to receive a vaccine. But by the time they arrived, the vaccines were no longer usable because they had been overheated.

Vaccines, Anurudh later learned, must be kept cool to stay effective. But refrigerating them requires electricity or ice – precious resources that many developing countries lack.

Although Anurudh eventually received the vaccine he needed, his experience as a baby and the sad reality that so many other children aren’t as lucky motivated him to take action. The high school student invented Vaxxwagon, a portable vaccine-carrying device that generates its own power to keep lifesaving medicines cool as they’re delivered to remote areas around the world.

Anurudh first got his idea for Vaxxwagon in 2014. He read several textbooks to learn everything he could about refrigeration, and then he did research online to learn more about vaccines. Rather than relying on electricity or ice, Anurudh figured out a way to use wheels to power a refrigeration system for about eight hours. The entire rechargeable cooling system can be pulled to areas in need of vaccines by a bicycle, a car, or an animal. Eventually, Anurudh took his design to professors at Johns Hopkins University for advice. Not only did they confirm Vaxxwagon could work, but they offered him funding to help build it.

Anurudh was rewarded with the 2015 Google Science Fair LEGO Education Builder Award for his invention. Anurudh says his final goal is to start selling Vaxxwagon to relief organizations, so it can be used to help people around the world.

Anurudh, who plans to pursue engineering degree in college, says, “Don’t give up on your ideas. But always try to help others with your projects. That’s the point of engineering – to help people.”

1. Why do many children die every year?
A.They lack qualified medical teams.
B.They cannot afford usable medicines.
C.They don’t have an electricity system.
D.They have no access to effective vaccines.
2. What is special about Vaxxwagon?
A.It can serve as a fridge.
B.It can produce safe vaccines.
C.It can detect deadly diseases.
D.It can be a means of transport.
3. Which of the following words can best describe Anurudh?
A.Caring and creative.
B.Modest and sympathetic.
C.Loyal and determined.
D.Honest and hard-working.
4. What can we learn from the story?
A.Practice makes perfect.
B.One good turn deserves another.
C.Motivation is the mother of success.
D.All things are difficult before they are easy.
2019-01-17更新 | 145次组卷
阅读理解-阅读单选(约370词) | 较难 (0.4)
文章大意:本文是一篇说明文。文章主要介绍了虚拟患者使临床试验快速可靠。

【推荐3】What if computers could replace patients? If virtual (虚拟的) humans could have replaced real people in some stages of a drug trial, it could have sped up development of a preventive tool and slowed down the spread of viruses. Similarly, potential drugs that weren’t likely to work could have been identified early, cutting trial costs and avoiding testing poor drug candidates on living volunteers. These are some of the benefits of “in silico medicine”, which is also known as “computational medicine”.

Powerful computers get to work based on the data according to some rules, producing a virtual organ (器官) that looks and behaves like the real thing. With virtual organs, the modeling begins by feeding data into a complex mathematical model of the mechanisms.

In silico clinical trials are already underway to an extent. For the foreseeable future, real patients will be needed in late-stage studies, but in silico trials will make it possible to conduct quick and inexpensive first assessments of safety and efficiency, hugely reducing the number of live human subjects required for experimentation.

The U.S. Food and Drug Administration (FDA), for instance, is using computer simulations (模拟) in place of human trials for evaluating new technology systems. The agency has also published guidance for designing trials of drugs and devices that include virtual patients.

Beyond speeding results and reducing the risks of clinical trials, in silico medicine can be used in place of risky interventions (干预) that are required for analyzing or planning treatment of certain medical conditions. For example, HeartFlow Analysis, a cloud-based service approved by the FDA, enables doctors to identify heart disease based on CT images of a patient’s heart. The HeartFlow system has used these images to construct a dynamic model of the blood running through the heart, thus identifying abnormal conditions and their severity. Without this technology, doctors would need to cut into the body to perform an angiogram (血管造影) to decide whether and how to intervene. Experimenting on digital models of individual patients can also help personalize treatment for any number of conditions.

1. What is the key factor of “in silico medicine”?
A.Trial costs.B.Virtual organs.
C.Potential drugs.D.Living volunteers.
2. What can we know about “in silico medicine”?
A.It is mainly used to try drugs.B.It is lacking in practical value.
C.It frees patients from clinical trials.D.It provides safety and reduces costs.
3. What can be inferred about HeartFlow Analysis?
A.It is being applied to FDA for use.B.It has given doctors practical help.
C.It models CT images of living patients.D.It functions on the basis of angiograms.
4. What is the main idea of the text?
A.Virtual medical science is developing rapidly.
B.Clinical trials of new drugs have been sped up.
C.Virtual patients make clinical trials fast and reliable.
D.Computers will replace human doctors in the future.
2022-08-15更新 | 201次组卷
共计 平均难度:一般